An observational study demonstrating the adherence and ease of
use of the injector device, RebiSmart (R)

J 2020

An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart (R)

VALIS, Martin, Jana SARLAKOVA, Simona HALUSKOVA, Blanka KLIMOVA, Pavel POTUZNIK et. al.

Základní údaje

Originální název

An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart (R)

Autoři

VALIS, Martin (203 Česká republika), Jana SARLAKOVA (203 Česká republika), Simona HALUSKOVA (203 Česká republika), Blanka KLIMOVA (203 Česká republika), Pavel POTUZNIK (203 Česká republika), Marek PETERKA (203 Česká republika), Kamil KUCA (203 Česká republika), Pavel ŠTOURAČ (203 Česká republika, domácí), Jan MARES (203 Česká republika) a Zbysek PAVELEK (203 Česká republika)

Vydání

EXPERT OPINION ON DRUG DELIVERY, ABINGDON, TAYLOR & FRANCIS LTD, 2020, 1742-5247

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.648

Kód RIV

RIV/00216224:14110/20:00116023

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1080/17425247.2020.1742694

UT WoS

000528167500001

Klíčová slova anglicky

Multiple Sclerosis; patients; adherence; treatment; use; RebiSmart

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 7. 2020 09:05, Mgr. Tereza Miškechová

Anotace

V originále

Background: Adherence to Multiple Sclerosis (MS) treatment is considered one of the crucial factors for ensuring optimal clinical outcomes. Research has shown that the use of self-injector devices improves patient compliance with treatment. Therefore, the main purpose of this study is to evaluate the ease of use of RebiSmart (R) 2.0 in clinically isolated syndrome/relapsing-remitting MS patients during 12 months treatment period. Methods: A total number of 290 subjects entered into data collection; 249 (86%) of them completed the whole 12 months study period. The primary endpoints and the secondary endpoints were assessed by the User Study Questionnaire. Adherence data were retrieved from RebiSmart (R) 2.0 (Menu - Dose History) on the respective patient's visit. Outcome measures also included Expanded Disability Status Score, Kurtzke Functional Systems, and Modified Social Support Survey, Modified Social Support Survey-5. Results: This study demonstrated a very high proportion (>95%) of patients with a positive rating of the overall ease of use and the overall convenience of RebiSmart (R). The proportion of patients with a positive rating of the ease of use by individual domains and the functions of RebiSmart (R) were also high (>80%). Conclusion: The findings demonstrate a very good perception of the usability of the device by patients overall and in its individual functions.

Citovat

VALIS, Martin, Jana SARLAKOVA, Simona HALUSKOVA, Blanka KLIMOVA, Pavel POTUZNIK, Marek PETERKA, Kamil KUCA, Pavel ŠTOURAČ, Jan MARES a Zbysek PAVELEK. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart (R). EXPERT OPINION ON DRUG DELIVERY. ABINGDON: TAYLOR & FRANCIS LTD, 2020, roč. 17, č. 5, s. 719-724. ISSN 1742-5247. Dostupné z: https://dx.doi.org/10.1080/17425247.2020.1742694.

@article{1670605,
   author = {Valis, Martin and Sarlakova, Jana and Haluskova, Simona and Klimova, Blanka and Potuznik, Pavel and Peterka, Marek and Kuca, Kamil and Štourač, Pavel and Mares, Jan and Pavelek, Zbysek},
   article_location = {ABINGDON},
   article_number = {5},
   doi = {http://dx.doi.org/10.1080/17425247.2020.1742694},
   keywords = {Multiple Sclerosis; patients; adherence; treatment; use; RebiSmart},
   language = {eng},
   issn = {1742-5247},
   journal = {EXPERT OPINION ON DRUG DELIVERY},
   title = {An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart (R)},
   url = {https://www.tandfonline.com/doi/abs/10.1080/17425247.2020.1742694?journalCode=iedd20},
   volume = {17},
   year = {2020}
}

TY  - JOUR
ID  - 1670605
AU  - Valis, Martin - Sarlakova, Jana - Haluskova, Simona - Klimova, Blanka - Potuznik, Pavel - Peterka, Marek - Kuca, Kamil - Štourač, Pavel - Mares, Jan - Pavelek, Zbysek
PY  - 2020
TI  - An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart (R)
JF  - EXPERT OPINION ON DRUG DELIVERY
VL  - 17
IS  - 5
SP  - 719-724
EP  - 719-724
PB  - TAYLOR & FRANCIS LTD
SN  - 17425247
KW  - Multiple Sclerosis
KW  - patients
KW  - adherence
KW  - treatment
KW  - use
KW  - RebiSmart
UR  - https://www.tandfonline.com/doi/abs/10.1080/17425247.2020.1742694?journalCode=iedd20
L2  - https://www.tandfonline.com/doi/abs/10.1080/17425247.2020.1742694?journalCode=iedd20
N2  - Background: Adherence to Multiple Sclerosis (MS) treatment is considered one of the crucial factors for ensuring optimal clinical outcomes. Research has shown that the use of self-injector devices improves patient compliance with treatment. Therefore, the main purpose of this study is to evaluate the ease of use of RebiSmart (R) 2.0 in clinically isolated syndrome/relapsing-remitting MS patients during 12 months treatment period. Methods: A total number of 290 subjects entered into data collection; 249 (86%) of them completed the whole 12 months study period. The primary endpoints and the secondary endpoints were assessed by the User Study Questionnaire. Adherence data were retrieved from RebiSmart (R) 2.0 (Menu - Dose History) on the respective patient's visit. Outcome measures also included Expanded Disability Status Score, Kurtzke Functional Systems, and Modified Social Support Survey, Modified Social Support Survey-5. Results: This study demonstrated a very high proportion (>95%) of patients with a positive rating of the overall ease of use and the overall convenience of RebiSmart (R). The proportion of patients with a positive rating of the ease of use by individual domains and the functions of RebiSmart (R) were also high (>80%). Conclusion: The findings demonstrate a very good perception of the usability of the device by patients overall and in its individual functions.
ER  -

VALIS, Martin, Jana SARLAKOVA, Simona HALUSKOVA, Blanka KLIMOVA, Pavel POTUZNIK, Marek PETERKA, Kamil KUCA, Pavel ŠTOURAČ, Jan MARES a Zbysek PAVELEK. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart (R). \textit{EXPERT OPINION ON DRUG DELIVERY}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2020, roč.~17, č.~5, s.~719-724. ISSN~1742-5247. Dostupné z: https://dx.doi.org/10.1080/17425247.2020.1742694.

Podrobný výpis o publikaci